Status:
UNKNOWN
SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY
Lead Sponsor:
IRCCS San Raffaele
Conditions:
COVID-19
Testosterone Deficiency
Eligibility:
MALE
18+ years
Brief Summary
The hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjec...
Detailed Description
Preliminary data suggests that male individuals are more susceptible to COVID-19 infection, at least in Western countries, and that their mortality rate is higher than female individuals. This would s...
Eligibility Criteria
Inclusion
- Patient Cohort:
- Male patients with an age \> 18 hospitalized in the departments dedicated to the care of patients affected by COVID-19 at the San Raffaele Hospital and with:
- biological samples positive for SARS-CoV-2;
- negative test but highly suggestive clinical and radiological picture;
- patients discharged from the emergency room with biological samples positive for SARS-CoV-2;
- ability to read and sign the informed consent
- Control Cohort:
- healthy donors with an age\> 18 accessing the IRCCS OSR Blood Donor Center;
- ability to read and sign the informed consent
Exclusion
- People with an age \< 18;
- incapacity to read and sign the informed consent
Key Trial Info
Start Date :
May 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 18 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06177002
Start Date
May 19 2020
End Date
May 18 2025
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Ospedale San Raffaele
Milan, Lombardy, Italy, 20132